PFE dividend yield over 6%

What happened: Pfizer's (NYSE: PFE) dividend yield has surged to over 6%, driven by a combination of factors including patent expirations for some of its key drugs, underperformance compared to peers like Eli Lilly, and a lingering impact from the COVID-19 pandemic. Despite these challenges, Pfizer has maintained its dividend, and analysts have recently upgraded the stock, citing its strong fundamentals and undervalued status.

Market impact: The pharmaceutical sector is affected, with investors seeking high-yielding stocks like Pfizer. The company's struggles have pushed its dividend yield to levels not seen in a decade, attracting income investors despite concerns about its long-term growth prospects. Meanwhile, other pharmaceutical companies with more robust pipelines, such as Eli Lilly, continue to gain favor.

What to watch next: In the coming months, investors should monitor Pfizer's Q2 earnings report (expected on May 2, 2023) for updates on its pipeline and revenue growth. Additionally, regulatory decisions on Pfizer's new drug applications, such as its breast cancer drug palbociclib, will be crucial in determining the company's future growth trajectory. Lastly, keep an eye on Pfizer's share price, as a sustained recovery could lead to a reduction in its dividend yield, potentially attracting more growth-oriented investors.